期刊文献+

盐酸美沙酮片治疗晚期癌症疼痛的临床观察

Clinical Trials of M ethadone Hydrochloride Tablets to Treat the Advanced Cancer Pain
下载PDF
导出
摘要 目的:比较美沙酮与硫酸吗啡控释片治疗中、重度癌痛的止痛效果和不良反应。方法:60例中、重度癌痛患者(应用第二阶梯止痛药不能缓解者),随机分为两组,治疗药物分别为美沙酮组和美施康定组,在用药后15天评价疼痛缓解率及不良反应。结果:疼痛缓解率美沙酮组为83.3%(25/30),美施康定组86.7%(26/30),差异无显著性(P>0.05)。美施康定组便秘、恶心及呕吐发生率显著高于美沙酮组,差异有显著性(P<0.05)。结论:美沙酮由于对中、重度癌痛的止痛效果好,副作用低,为治疗中、重度癌痛较好的药物。 Objectives: To compare the analgesic effect and side effects between methadone hydrochloride tablets and morphine sulfate controlled-release tablets (MST). Methods: 60 patients with moderate or severe cancer pain were randomly divided into two groups. One groups was methadone hydrochloride tablets group (experiment group),another was MST group(control group). To evaluate the effective rates and side effects after using of the two medicines 15 days later. Results: The relieving rate of cancer pain is 83.3%(25/30)(experiment group) and 86.7%(26/30) (control group). There was no statistically significant difference between the two groups(P>0.05). The occurring rate of constipation,nausea and vomit of control group is higher than that of experiment group. There were statistically significant differences between the two groups (P<0.05). Conclusions: Methadone hydrochloride tablets has good effects to relieve moderate or severe cancer pain and it has low side effects. A methadone hydrochloride tablet is a better medicine to treat moderate or severe cancer pain.
出处 《岭南急诊医学杂志》 2004年第2期112-113,115,共3页 Lingnan Journal of Emergency Medicine
关键词 盐酸美沙酮片 治疗 晚期癌症 疼痛 不良反应 美施康定 cancer pain methadone hydrochloride tablet morphine sulfate controlled-release tablets
  • 相关文献

参考文献3

二级参考文献15

  • 1Ripamonti C, Dickerson ED. Strategies for the treatment of cancery pain in the new millennium. Drugs, 2001,61: 955-977.
  • 2Dundee JW, Clarke RSJ, McCaughey W, ed. Clinical anaesthetic pharmacology. Edinbrugh: Churchill Livingstone, 1991.214.
  • 3Mancini I, Lossignol DA, Body JJ. Opioid switching to oral methadone in cancer pain. Curr Opin Oncol, 2000, 12:308-313.
  • 4Boulton DW, Arnaud P, De Vane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers. Clin Pharmacol Ther,2001, 70:48-57.
  • 5Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain, 1997, 70:109-115.
  • 6Lawlor PG, Turner K, Hanson J, et al. Dose ratio between morphine to oral methadone in patients with cancer pain:a retrospective study.Cancer, 1998, 82:1167-1173.
  • 7Reynolds JEF, ed. Martindale. The extra pharmacopoeia. London:Royal Pharmaceut Soc, 1996.60-62.
  • 8Abramson FP. Methadone plasma protein binding: alterations in cancer and displacement from at-acid glycoprotein. Clin Pharmacol Ther, 1982, 32: 652-658.
  • 9Inturrisi CE, Porteney RK, Max MB, et al. Pharmacokineticpharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther, 1990, 47: 565-577.
  • 10Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther, 1987, 41: 392-401.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部